Meet the International Psoriasis Council’s Newest Board of Directors and Fellows

January 6, 2025

Deucravacitinib Hits Primary Endpoints in Two Phase 3 PsA Studies

December 23, 2024

U.S. FDA Approves Celltrion’s STELARA Biosimilar

December 18, 2024

Business News: AbbVie to Acquire Nimble Therapeutics and Its Oral Peptide IL23R Inhibitor

December 13, 2024

Ultraprocessed Foods May Up Risk for Psoriasis

November 27, 2024

Mindera Health, NPF Partner to Advance Precision Medicine in Psoriasis

November 19, 2024

PsO Pipeline Update: Icotrokinra, an Oral IL-23 Blocker, Looks Good in Topline Phase 3 Data

November 18, 2024

Johnson & Johnson Debuts Tremfya Clearance Photo Library

October 25, 2024

InnoCare’s TYK2 Performs Well in Phase II PsO Study

October 9, 2024

La La Anthony Partners With Amgen to Encourage Psoriasis Patients To Speak Up

October 4, 2024

Deucravacitinib (Sotyktu) Meets Main Goals in Phase 3b/4 Scalp PsO Study

September 27, 2024

Stress May Kickstart Psoriasis Flare-ups

September 27, 2024